Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Sintilimab - Eli Lilly and Company/Innovent Biologics

Next Previous
Drug Profile

Sintilimab - Eli Lilly and Company/Innovent Biologics

Alternative Names: Anti-PD-1 antibody - Eli Lilly and Company/Innovent Biologics; IBI 308; LY-3342901; Sintilimab injection; Sintilimab injection - Eli Lilly and Company/Innovent Biologics; Tyvyt; Xindili Dankang

Latest Information Update: 22 Sep 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Adimab; Innovent Biologics
  • Developer Chinese Academy of Medical Sciences; Eli Lilly and Company; Fujian Cancer Hospital; HUTCHMED; Innovent Biologics; Jiangsu Hengrui Medicine Co.; Jiangsu Provincial Peoples Hospital; Laekna Therapeutics; Shanghai Jiaotong University School of Medicine; Sun Yat-Sen University
  • Class Antineoplastics; Immunotherapies; Monoclonal antibodies
  • Mechanism of Action Antibody-dependent cell cytotoxicity; Programmed cell death 1 receptor antagonists; T lymphocyte stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Endometrial cancer; Gastric cancer; Hodgkin's disease; Liver cancer; Non-small cell lung cancer; Oesophageal cancer
  • Preregistration Renal cell carcinoma
  • Phase III Acral lentiginous melanoma; Colorectal cancer; Nasopharyngeal cancer
  • Phase II Cervical cancer; Extranodal NK-T-cell lymphoma; Small cell lung cancer
  • Phase I/II Solid tumours
  • Phase I Cancer; Lung cancer; Lymphoma

Most Recent Events

  • 22 Sep 2025 Launched for Endometrial cancer (Second-line therapy or greater, Metastatic disease, Late-stage disease, Inoperable/Unresectable, Combination therapy) in China (IV) prior to September 2025
  • 22 Sep 2025 Launched for Non-small cell lung cancer (Second-line therapy or greater, Combination therapy, Late-stage disease, Metastatic disease) in China (IV) prior to September 2025
  • 04 Jun 2025 Preregistration for Renal cell carcinoma (Late-stage disease, Combination therapy, Metastatic disease, Second-line therapy or greater) in China (IV)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top